• Eton Pharmaceuticals Acquires U.S. Commercialization Rights to Hemangeol from Pierre Fabre
Eton Pharmaceuticals - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Tuesday recap

NewsDealsSocialBlogsVideosPodcasts
HomeEton Pharmaceuticals
Eton Pharmaceuticals logo

Eton Pharmaceuticals

0 followers

ETON

Performance

About Eton Pharmaceuticals

Eton Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company maintains a diversified portfolio of approved products, including Alkindi Sprinkle, Carglumic Acid, Increlex, Nitisinone, PKU GoLike, Galzin, and Khindivi, among others, with a pipeline of additional candidates. Headquartered in Deer Park, Illinois, Eton advances its products through development and, where appropriate, partnerships to bring therapies to patients with limited treatment options. The company emphasizes rapid commercialization and meaningful impact for small patient populations worldwide.

Recent News

No recent news for this company.

Recent Deals

Eton Pharmaceuticals Acquires U.S. Commercialization Rights to Hemangeol From Pierre Fabre

March 2, 2026

Key Team Members

Scott Grossenbach

Senior Vice President, Sales Operations

Sean Brynjelsen

Chief Executive Officer & Director

Danka Radosavljevic

Senior Vice President, Quality and Operations

David Krempa

Chief Business Officer

Kevin Guthrie

Executive Vice-President, Commercial Operations

Key Facts

HQ Location

Deer Park, United States

Founded

2017

Employees

11 - 50

Status

Public

Website

https://etonpharma.com